{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:39:37Z","timestamp":1789421977488,"version":"build-2803163510"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.imlet.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T11:12:30Z","timestamp":1556017950000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Vaccine platforms for the prevention of Lassa fever"],"prefix":"10.1016","volume":"215","author":[{"given":"Jyothi","family":"Purushotham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"July4","key":"10.1016\/j.imlet.2019.03.008_bib0005","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4269\/ajtmh.1970.19.680","article-title":"Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus","volume":"19","author":"Buckley","year":"1970","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","article-title":"A prospective study of the epidemiology and ecology of Lassa fever","volume":"155","author":"Mccormick","year":"1987","journal-title":"J. Infect. Dis."},{"issue":"7426","key":"10.1016\/j.imlet.2019.03.008_bib0015","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.327.7426.1271","article-title":"Lassa fever: epidemiology, clinical features, and social consequences","volume":"327","author":"Kay Richmond","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-016-0621-4","article-title":"Serosurveillance of viral pathogens circulating in West Africa","volume":"13","author":"O\u2019Hearn","year":"2016","journal-title":"Virol. J."},{"issue":"12","key":"10.1016\/j.imlet.2019.03.008_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pntd.0002582","article-title":"Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali","volume":"7","author":"Safronetz","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"4","key":"10.1016\/j.imlet.2019.03.008_bib0030","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4269\/ajtmh.16-0821","article-title":"Annual incidence of Lassa virus infection in southern Mali","volume":"96","author":"Safronetz","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"8","key":"10.1016\/j.imlet.2019.03.008_bib0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/trstmh\/trv047","article-title":"Mapping the zoonotic niche of Lassa fever in Africa","volume":"109","author":"Mylne","year":"2015","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.imlet.2019.03.008_bib0040","series-title":"Nigeria Centre for Disease Control. Week 52. Weekly Epidemiological Report [Internet]","year":"2018"},{"issue":"6381","key":"10.1016\/j.imlet.2019.03.008_bib0045","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.359.6381.1201","article-title":"Nigeria hit by unprecedented Lassa fever outbreak","volume":"359","author":"Roberts","year":"2018","journal-title":"Science"},{"issue":"3\u20134","key":"10.1016\/j.imlet.2019.03.008_bib0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01310811","article-title":"Ribonucleic acids of Machupo and Lassa viruses","volume":"79","author":"Lukashevich","year":"1984","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virol.2003.09.009","article-title":"Sequence analysis of l RNA of Lassa virus","volume":"318","author":"Vieth","year":"2004","journal-title":"Virology."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0060","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1128\/jvi.52.3.897-904.1984","article-title":"Sequencing studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral S RNA","volume":"52","author":"Auperin","year":"1984","journal-title":"J. Virol."},{"issue":"July2","key":"10.1016\/j.imlet.2019.03.008_bib0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0042-6822(85)90278-8","article-title":"Molecular cloning of Lassa virus RNA: nucleotide sequence and expression of the nucleocapsid protein gene","volume":"144","author":"Clegg","year":"1985","journal-title":"Virology"},{"issue":"15","key":"10.1016\/j.imlet.2019.03.008_bib0070","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1128\/JVI.00651-15","article-title":"Molecular mechanism for LAMP1 recognition by Lassa virus","volume":"89","author":"Cohen-Dvashi","year":"2015","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.imlet.2019.03.008_bib0075","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1128\/jvi.61.4.982-985.1987","article-title":"Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins","volume":"61","author":"Buchmeier","year":"1987","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.imlet.2019.03.008_bib0080","doi-asserted-by":"crossref","first-page":"e1005418","DOI":"10.1371\/journal.ppat.1005418","article-title":"Acidic pH-Induced conformations and LAMP1 binding of the Lassa virus glycoprotein spike","volume":"12","author":"Li","year":"2016","journal-title":"PLoS Pathog."},{"issue":"11544","key":"10.1016\/j.imlet.2019.03.008_bib0085","first-page":"1","article-title":"Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits","volume":"7","author":"Robinson","year":"2016","journal-title":"Nat. Commun."},{"issue":"80","key":"10.1016\/j.imlet.2019.03.008_bib0090","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0095","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.4049\/jimmunol.180.5.3113","article-title":"Absence of CTL responses to early viral antigens facilitates viral persistence","volume":"180","author":"Schildknecht","year":"2008","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.imlet.2019.03.008_bib0100","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","article-title":"A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity","volume":"25","author":"Carrion","year":"2007","journal-title":"Vaccine"},{"issue":"March5","key":"10.1016\/j.imlet.2019.03.008_bib0105","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/JVI.74.5.2186-2192.2000","article-title":"Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein","volume":"74","author":"ter Meulen","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.imlet.2019.03.008_bib0110","doi-asserted-by":"crossref","first-page":"25280","DOI":"10.1038\/srep25280","article-title":"New hosts of the lassa virus","volume":"6","author":"Olayemi","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.imlet.2019.03.008_bib0115","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","article-title":"Clinical sequencing uncovers origins and evolution of Lassa virus","volume":"162","author":"Andersen","year":"2015","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.imlet.2019.03.008_bib0120","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1128\/JVI.74.15.6992-7004.2000","article-title":"Genetic diversity among Lassa virus strains","volume":"74","author":"Bowen","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.imlet.2019.03.008_bib0125","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3389\/fmicb.2015.01037","article-title":"Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage","volume":"6","author":"Manning","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.imlet.2019.03.008_bib0130","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3201\/eid2403.171905","article-title":"New lineage of Lassa virus, Togo, 2016","volume":"24","author":"Whitmer","year":"2018","journal-title":"Emerg. Infect. Dis. U. S."},{"issue":"11","key":"10.1016\/j.imlet.2019.03.008_bib0135","doi-asserted-by":"crossref","first-page":"e0006971","DOI":"10.1371\/journal.pntd.0006971","article-title":"Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria","volume":"12","author":"Oloniniyi","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"6422","key":"10.1016\/j.imlet.2019.03.008_bib0140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1126\/science.aav8958","article-title":"Understanding Lassa fever","volume":"363","author":"Bhadelia","year":"2019","journal-title":"Science"},{"issue":"80","key":"10.1016\/j.imlet.2019.03.008_bib0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aau9343","article-title":"Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak","volume":"363","author":"Kafetzopoulou","year":"2019","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.imlet.2019.03.008_bib0150","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa1804498","article-title":"Genomic analysis of Lassa virus during an increase in cases in Nigeria in 2018","volume":"379","author":"Siddle","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.imlet.2019.03.008_bib0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4269\/ajtmh.1970.19.670","article-title":"Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings","volume":"19","author":"Frame","year":"1970","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/infdis\/155.3.445","article-title":"A case-control study of the clinical diagnosis and course of Lassa fever","volume":"155","author":"McCormick","year":"1987","journal-title":"J. Infect. Dis."},{"issue":"6648","key":"10.1016\/j.imlet.2019.03.008_bib0165","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.297.6648.584","article-title":"A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy","volume":"297","author":"Price","year":"1988","journal-title":"Br. Med. J."},{"issue":"2","key":"10.1016\/j.imlet.2019.03.008_bib0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4269\/ajtmh.1986.35.401","article-title":"Lassa virus hepatitis: a study of fatal Lassa fever in humans","volume":"35","author":"McCormick","year":"1986","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"16","key":"10.1016\/j.imlet.2019.03.008_bib0175","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/jama.1990.03450160063030","article-title":"Acute sensorineural deafness in Lassa fever","volume":"264","author":"Cummins","year":"1990","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.imlet.2019.03.008_bib0180","doi-asserted-by":"crossref","first-page":"e0006187","DOI":"10.1371\/journal.pntd.0006187","article-title":"Lassa fever\u2013induced sensorineural hearing loss: a neglected public health and social burden","volume":"12","author":"Mateer","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"January1","key":"10.1016\/j.imlet.2019.03.008_bib0185","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2019.03.008_bib0190","unstructured":"US Army Medical Research and Material Command. Intravenous ribavirin protocol to treat individuals with viral hemorrhagic fever."},{"key":"10.1016\/j.imlet.2019.03.008_bib0195","unstructured":"US Army Medical Research and Material Command. Treatment of viral hemorrhagic fevers with intravenous ribavirin in military treatment facilities."},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0200","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.172.5.2861","article-title":"Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells","volume":"172","author":"Baize","year":"2004","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.imlet.2019.03.008_bib0205","doi-asserted-by":"crossref","first-page":"e1007430","DOI":"10.1371\/journal.ppat.1007430","article-title":"Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells","volume":"14","author":"Schaeffer","year":"2018","journal-title":"PLoS Pathog."},{"issue":"19","key":"10.1016\/j.imlet.2019.03.008_bib0210","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1128\/JVI.78.19.10516-10524.2004","article-title":"Human macrophages, but not dendritic cells, are activated and produce alpha\/beta interferons in response to Mopeia virus infection","volume":"78","author":"Pannetier","year":"2004","journal-title":"J. Virol."},{"issue":"16","key":"10.1016\/j.imlet.2019.03.008_bib0215","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1128\/JVI.02120-10","article-title":"Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus","volume":"85","author":"Pannetier","year":"2011","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0220","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.micinf.2006.02.002","article-title":"Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages","volume":"8","author":"Baize","year":"2006","journal-title":"Microbes Infect."},{"issue":"6","key":"10.1016\/j.imlet.2019.03.008_bib0225","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1128\/JVI.06284-11","article-title":"Functional interferon system is required for clearance of Lassa virus","volume":"86","author":"Yun","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0230","doi-asserted-by":"crossref","first-page":"e1005656","DOI":"10.1371\/journal.ppat.1005656","article-title":"Chimeric mice with competent hematopoietic immunity reproduce key features of severe Lassa fever","volume":"12","author":"Oestereich","year":"2016","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.imlet.2019.03.008_bib0235","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1128\/JVI.01948-08","article-title":"Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys","volume":"83","author":"Baize","year":"2009","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0240","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","article-title":"Clinical virology of Lassa fever in hospitalized patients","volume":"155","author":"Johnson","year":"1987","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0245","doi-asserted-by":"crossref","first-page":"e1000836","DOI":"10.1371\/journal.ppat.1000836","article-title":"T cell-dependence of Lassa fever pathogenesis","volume":"6","author":"Flatz","year":"2010","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.1890370102","article-title":"Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys","volume":"37","author":"McCormick","year":"1992","journal-title":"J. Med. Virol."},{"issue":"8","key":"10.1016\/j.imlet.2019.03.008_bib0255","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","article-title":"Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model","volume":"30","author":"Goicochea","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.imlet.2019.03.008_bib0260","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1371\/journal.pmed.0020183","article-title":"Development of a new vaccine for the prevention of Lassa fever","volume":"2","author":"Geisbert","year":"2005","journal-title":"PLoS Med."},{"issue":"33","key":"10.1016\/j.imlet.2019.03.008_bib0265","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2008.05.046","article-title":"Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen","volume":"26","author":"Thompson","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF01313953","article-title":"Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies","volume":"106","author":"Hufert","year":"1989","journal-title":"Arch. Virol."},{"issue":"23","key":"10.1016\/j.imlet.2019.03.008_bib0275","doi-asserted-by":"crossref","first-page":"16949","DOI":"10.1074\/jbc.M112.420521","article-title":"Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppression","volume":"288","author":"Jiang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"September","key":"10.1016\/j.imlet.2019.03.008_bib0280","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies","volume":"133","author":"Cross","year":"2016","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.imlet.2019.03.008_bib0285","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0290","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-018-0049-5","article-title":"Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development","volume":"3","author":"Hallam","year":"2018","journal-title":"Npj Vacc."},{"issue":"October 19","key":"10.1016\/j.imlet.2019.03.008_bib0300","article-title":"Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus","volume":"87","author":"Yun","year":"2013","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.imlet.2019.03.008_bib0305","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","article-title":"Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 \u2009mouse model","volume":"30","author":"Goicochea","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0310","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","volume":"36","author":"Wang","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2019.03.008_bib0315","series-title":"GeoVax. GeoVax Reports Promising Results for Lassa Fever Vaccine","year":"2017"},{"issue":"2","key":"10.1016\/j.imlet.2019.03.008_bib0320","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","article-title":"Pathogenesis of Lassa virus infection in guinea pigs","volume":"37","author":"Jahrling","year":"1982","journal-title":"Infect. Immun."},{"key":"10.1016\/j.imlet.2019.03.008_bib0325","first-page":"5","article-title":"Experimental studies of arenaviral hemorrhagic fevers","volume":"134","author":"Peters","year":"1987","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.imlet.2019.03.008_bib0330","doi-asserted-by":"crossref","first-page":"14775","DOI":"10.1038\/srep14775","article-title":"The broad-spectrum antiviral Favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset","volume":"5","author":"Safronetz","year":"2015","journal-title":"Sci. Rep."},{"issue":"8552","key":"10.1016\/j.imlet.2019.03.008_bib0335","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever","volume":"2","author":"Clegg","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.imlet.2019.03.008_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0003736","article-title":"A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses","volume":"9","author":"Safronetz","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"May5","key":"10.1016\/j.imlet.2019.03.008_bib0345","first-page":"580","article-title":"Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin","volume":"141","author":"Stephen","year":"1980","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.imlet.2019.03.008_bib0350","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1743-422X-8-205","article-title":"Pathogenesis of Lassa fever in cynomolgus macaques","volume":"8","author":"Hensley","year":"2011","journal-title":"Virol. J."},{"issue":"12","key":"10.1016\/j.imlet.2019.03.008_bib0355","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1128\/JVI.02876-06","article-title":"Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues","volume":"81","author":"Carrion","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.imlet.2019.03.008_bib0360","series-title":"Inovio Pharmaceuticals. Safety, tolerability and immunogenicity of INO-4500 in healthy volunteers","year":"2019"},{"key":"10.1016\/j.imlet.2019.03.008_bib0365","series-title":"WHO Target Product Profile for Lassa Virus Vaccine","year":"2017"},{"issue":"11","key":"10.1016\/j.imlet.2019.03.008_bib0370","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/v4112514","article-title":"Advanced vaccine candidates for Lassa fever","volume":"4","author":"Lukashevich","year":"2012","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0375","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0042-6822(89)90525-4","article-title":"Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus","volume":"171","author":"Morrison","year":"1989","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0380","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1073\/pnas.86.1.317","article-title":"Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene","volume":"86","author":"Fisher-Hoch","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"August15","key":"10.1016\/j.imlet.2019.03.008_bib0385","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1128\/JVI.74.15.6777-6783.2000","article-title":"Effective vaccine for Lassa fever","volume":"74","author":"Fisher-Hoch","year":"2000","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0390","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.vaccine.2009.09.098","article-title":"Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses","volume":"28","author":"Guy","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.imlet.2019.03.008_bib0395","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"issue":"February6","key":"10.1016\/j.imlet.2019.03.008_bib0400","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.imlet.2019.03.008_bib0405","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14760584.2016.1184575","article-title":"Vaccine platforms to control Lassa fever","volume":"15","author":"Lukashevich","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"23","key":"10.1016\/j.imlet.2019.03.008_bib0410","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J. Virol."},{"issue":"September41","key":"10.1016\/j.imlet.2019.03.008_bib0415","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1016\/j.vaccine.2008.07.057","article-title":"Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates","volume":"26","author":"Lukashevich","year":"2008","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.imlet.2019.03.008_bib0420","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1128\/JVI.79.22.13934-13942.2005","article-title":"A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses","volume":"79","author":"Lukashevich","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.imlet.2019.03.008_bib0425","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1743-422X-10-52","article-title":"An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity","volume":"10","author":"Zapata","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.imlet.2019.03.008_bib0430","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/vaccines1030262","article-title":"Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa virus in a guinea pig disease model when delivered by dermal electroporation","volume":"1","author":"Cashman","year":"2013","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.imlet.2019.03.008_bib0435","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","article-title":"A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever","volume":"13","author":"Cashman","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.imlet.2019.03.008_bib0440","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-restrepo","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0445","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV ZEBOV-GP \u2013 mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J. Virol. Methods"},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/imm.12829","article-title":"Novel viral vectors in infectious diseases","volume":"153","author":"Humphreys","year":"2018","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.imlet.2019.03.008_bib0460","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.imlet.2019.03.008_bib0465","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSVG-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.imlet.2019.03.008_bib0470","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"12","key":"10.1016\/j.imlet.2019.03.008_bib0475","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1128\/JVI.03441-13","article-title":"Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates","volume":"88","author":"Clarke","year":"2014","journal-title":"J. Virol."},{"issue":"7549","key":"10.1016\/j.imlet.2019.03.008_bib0480","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"Mire","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2019.03.008_bib0485","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus","volume":"212","author":"Matassov","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.01190-17","article-title":"Single-dose trivalent VesiculoVax vaccine protects macaques from lethal Ebolavirus and Marburgvirus challenge","volume":"92","author":"Matassov","year":"2018","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.imlet.2019.03.008_bib0495","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.micinf.2018.01.005","article-title":"Measles-derived vaccines to prevent emerging viral diseases","volume":"20","author":"Frantz","year":"2018","journal-title":"Microbes Infect."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0500","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.virol.2003.12.013","article-title":"Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones","volume":"321","author":"ter","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.imlet.2019.03.008_bib0505","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.imlet.2019.03.008_bib0510","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.imlet.2019.03.008_bib0515","first-page":"3501","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy","volume":"27","author":"Dudareva","year":"2009","journal-title":"Vaccine Netherlands"},{"issue":"9653","key":"10.1016\/j.imlet.2019.03.008_bib0520","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.imlet.2019.03.008_bib0525","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/sj.gt.3302675","article-title":"Chimpanzee-origin adenovirus vectors as vaccine carriers","volume":"13","author":"Tatsis","year":"2006","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.imlet.2019.03.008_bib0530","doi-asserted-by":"crossref","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2019.03.008_bib0535","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-017-0029-1","article-title":"Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model","volume":"2","author":"Munster","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.imlet.2019.03.008_bib0540","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.imlet.2019.03.008_bib0545","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.imlet.2019.03.008_bib0550","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41467-018-04859-5","article-title":"Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors","volume":"9","author":"L\u00f3pez-Camacho","year":"2018","journal-title":"Nat. Commun."},{"issue":"30","key":"10.1016\/j.imlet.2019.03.008_bib0555","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2017.05.032","article-title":"ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice","volume":"35","author":"Alharbi","year":"2017","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.imlet.2019.03.008_bib0560","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/mt.2013.284","article-title":"Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza a antigens","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.imlet.2019.03.008_bib0565","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus a in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.imlet.2019.03.008_bib0570","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and immunogenicity of ChAd63 and MVA ME-TRAP in west African children and infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.imlet.2019.03.008_bib0575","first-page":"1","article-title":"Safety and immunogenicity of malaria vectored vaccines given with routine expanded program on immunization vaccines in Gambian infants and neonates: a randomized controlled trial","volume":"8","author":"John","year":"2017","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2019.03.008_bib0580","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ymthe.2016.11.003","article-title":"Viral vector malaria vaccines induce high-level t cell and antibody responses in west African children and infants","volume":"25","author":"Bliss","year":"2017","journal-title":"Mol. Ther."},{"issue":"20","key":"10.1016\/j.imlet.2019.03.008_bib0585","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.vaccine.2016.03.061","article-title":"Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle","volume":"34","author":"Dulal","year":"2016","journal-title":"Vaccine"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247819300483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247819300483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:35:45Z","timestamp":1759044945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247819300483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":117,"alternative-id":["S0165247819300483"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2019.03.008","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine platforms for the prevention of Lassa fever","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}